Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Disease
- Drug Discovery
- Diabetes Treatment
- Medical
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 285725
License Grant
The Institute, a not-for-profit corporation, granted Licensee an exclusive, worldwide license, with the right to grant sublicenses to non-affiliate third parties, to develop, make, have made, use, sell, offer for sale and import certain products for use in the field of fatty liver disease in humans receiving total parenteral nutrition, by administering, as monotherapy, a pharmaceutical composition comprising intravenous choline, wherein the fatty liver disease is selected from IFALD, non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH), NASH-associated liver fibrosis, or non-alcoholic cirrhosis. Notwithstanding the exclusive rights granted to Licensee, the Institute shall retain the right to make, use and practice such patents in its own laboratories solely for non-commercial scientific purposes and for continued non-commercial research.
License Property
U.S. patent related to the treatment of fatty liver disease in humans. The ucts are use in the field of fatty liver disease in humans receiving total parenteral nutrition, by administering, as monotherapy, a pharmaceutical composition comprising intravenous choline, wherein the fatty liver disease is selected from IFALD, non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH), NASH-associated liver fibrosis, or non-alcoholic cirrhosis.
Field of Use
Fatty liver disease also known as hepatic steatosis, is a condition where excess fat builds up in the liver. Fatty liver disease is very common with the incidence increasing with the obesity epidemic. Major risk factors include obesity and type 2 diabetes, though it's also associated with excessive alcohol consumption.
IPSCIO Record ID: 378328
License Grant
Licensee was granted an exclusive license to use the MP Patents and know-how to develop products for the development, commercialization and exclusive license of MLR-1023 On October 20, 2021, Licensee expanded the an exclusive licensing agreement with Licensor to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation.
License Property
MLR-1023 (tolimidone) is being developed as a novel therapeutic for Type 1 diabetes with a focus on C-peptide positive patients. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies.
Field of Use
The license of MLR-1023 (tolimidone) is for the purpose of developing a novel therapeutic for Type 1 diabetes.
Field of use is for the treatment of diabetes as well as for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions.
Diabetes is a chronic (long-lasting) health condition that affects how your body turns food into energy. Most of the food you eat is broken down into sugar (also called glucose) and released into your bloodstream. When your blood sugar goes up, it signals your pancreas to release insulin.
Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.
Pulmonary inflammation is acute lung inflammation. In the lung, inflammation is usually caused by pathogens or by exposure to toxins, pollutants, irritants, and allergens. During inflammation, numerous types of inflammatory cells are activated.
IPSCIO Record ID: 285482
License Grant
Licensor, individual and a shareholder in the company, granted the Company an exclusive, worldwide, non-transferable license in and to certain licensed orphan designations, certain licensed IND, certain existing study data and to certain licensed know-how to develop, make, use, sell, offer for sale and import the licensed product during the term of the Choline Agreement.
License Property
The IND (Investigational New Drug), ODDs (Orphan Drug Designations and other regulatory assets are related to IV Choline Chloride.
IV Choline Chloride is an intravenous (IV) substrate replacement therapy initially in development for patients receiving parenteral (typically intravenous) nutrition (PN) who have intestinal failure associated liver disease (IFALD). Choline is a known important substrate for phospholipids that are critical for healthy liver function. Because PN patients cannot sufficiently absorb adequate levels of choline and no available PN components contain sufficient amounts of choline to correct this deficit, PN patients often experience a prolonged progression to hepatic failure and death, with the only known intervention being a dual small bowel / liver transplant.
IFALD is associated with significant morbidity in patients who rely on PN for long-term survival. It is believed that there are multiple contributing factors to the development of IFALD with a substantial body of literature pointing to choline deficiency as a key cause. IFALD is uniquely characterized by the presence of both steatosis (toxic fat accumulation in liver cells) and cholestasis (damage to the biliary system in the liver) in patients who are chronic (greater than six months) PN users.
Field of Use
Choline Chloride for Injection is a replacement therapy for patients receiving parenteral nutrition (PN) who are choline deficient. Choline Chloride for Injection has been granted Orphan Drug Designations by the FDA for both the treatment and prevention of Intestinal Failure Associated Liver Disease (IFALD). Choline Chloride for Injection has shown promising results in both reversing steatosis and improving cholestasis in patients dependent on PN and who are also choline deficient. Steatosis and cholestasis are the hallmark pathologies of IFALD. It is estimated that over 80% of patients dependent on PN are unable to adequately synthesize choline, a key precursor to phospholipids critical in the export of triglycerides from the liver, as well as maintenance of healthy bile composition in the biliary system. A significant body of literature suggests that choline deficiency plays a critical role in the frequent development of IFALD in patients dependent on PN.
IPSCIO Record ID: 25836
License Grant
The Israeli Licensee entered into a Research, Option and License Agreement with the Spanish Licensor for the development of a non-invasive, blood-based companion diagnostic tool.
License Property
The Licensor develops a test for determining steatosis and NASH. Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease.
Licensed product is a non-invasive blood test including metabolic markers that could potentially predict therapeutic responses to AramcholTM, Galmed’s once-daily, oral therapy for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.
Field of Use
The Licensee has an option to exclusively license a companion diagnostic tool for NASH using AramcholTM.
IPSCIO Record ID: 256262
License Grant
The Licensors grant an exclusive license in the Territory under the Licensed Patents and Information for all purposes, including without limitation, to develop, use, make, have made, import, have imported, export, have exported, offer for sale, have sold and sell Licensed Products.
License Property
The patents are for anti-fibrotic uses of Pirfenidon.
'Licensed Patents' means that certain U.S. Patent No. 5,310,562 with respect to the anti-fibrotic uses of Pirfenidon.
Field of Use
The field of use is for the therapeutic treatment of a specific fibrotic human disease.
The Licensee licensed the rights to develop and commercialize pirfenidone for all fibrotic diseases, including renal, liver and pulmonary fibrosis.
Fibrosis, or the accumulation of extracellular matrix molecules that make up scar tissue, is a common feature of chronic tissue injury. Pulmonary fibrosis, renal fibrosis, and hepatic cirrhosis are among the more common fibrotic diseases, which in aggregate represent a huge unmet clinical need.
IPSCIO Record ID: 282741
License Grant
Licensor granted Licensee an exclusive royalty-bearing license to research, develop, manufacture and commercialize pharmaceutical products comprising, as an active ingredient, gemcabene in mainland China, Hong Kong, Macau and Taiwan (each, a region, and collectively, the Territory). Licesor retains all rights to gemcabene outside of the Territory. The parties have agreed to collaborate with respect to development and commercialization activities under the Licensee License Agreement through a joint steering committee composed of an equal number of representatives of both parties.
License Property
Licensed Product are products containing gemcabene.
Licensor is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease (NAFLD/NASH).
Licensors product candidate, gemcabene, has been tested as monotherapy and in combination with statins and other drugs in multiple Phase 1 and Phase 2 clinical trials.
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
